Research programme: cancer therapeutics - Coronado BiosciencesAlternative Names: 8r; Apogossypol; CNDO 103
Latest Information Update: 09 Aug 2012
At a glance
- Originator The Burnham Institute
- Developer Coronado Biosciences
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer